Exclusives

A 40-patient RCT will assess the safety and efficacy of NOX1416 in the treatment of chronic, non-healing DFUs with primary outcome of number of patients with Methemoglobin > 5% and adverse events at 12 weeks. Not yet recruiting; estimated...

DeRoyal Industries received FDA 510(k) clearance for the Prospera Spectruum NPWT system, a portable, rechargeable NPWT system that can apply continuous or variable pressure from 25mmHG to 200mmHG.

It was recently announced that Heberprot-P, a recombinant epidermal growth factor developed in Cuba, has been approved by the US FDA for the biotechnology company Discovery Therapeutics Caribe (DTC) to conduct a Phase III study of the drug in...

Omeza presents final clinical data showing that Omeza plus offloading achieved a 94% area reduction (PAR) in DFUs at 12 weeks and 62% PAR at 4 weeks. Further studies to evaluate Omeza in VLUs are underway.

A 40-patient study of vascular patients who underwent closure of groin incisions for Critical Limb Threatening Ischemia (CLTI) found that those who received Prevena NPWT had significantly reduced rates of infection, reoperation, and...

A multicenter RCT investigated the effectiveness of AQUACEL Ag+ Extra in the management of patients with VLUs. The study found that VLUs managed with AQUACEL Ag+ Extra were 31% more likely to heal completely at 12 weeks and 31% more likely to...

A 40-patient RCT compared activated carbon cloth (Zorflex) and silver-based dressings in a population with DFU. The primary endpoint was wound area reduction. The study suggests that activated carbon promotes better DFU healing.

A 600-patient observational registry will examine the safety and outcomes of using Kerecis fish skin grafts in US medical settings with primary outcome of percentage of failures, allergies, or infections at 12 months. Recruitment is ongoing...